Schrödinger's collaborated drug, zasocitinib, is currently in Phase III clinical trials, while Insilico Medicine's Rentosertib, a fully AI-discovered and designed drug, is in Phase II, and Exscientia was among the first to bring an AI-designed molecule into human trials.